Recently Visited
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
Most Searched
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
Search results for {{searchTermHome}}
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} | Score
{{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
No Matches Found
Loading...
Is PolyPid Ltd. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for PolyPid Ltd. to determine a bullish or bearish outlook.
Who are in the management team of PolyPid Ltd.?
As of March 2022, the management team of PolyPid Ltd. includes Mrs. Anat Segal (Chairperson), Mr. Amir Weisberg (CEO and Director), Mr. Jack Kyiet (COO and Director), and Dr. Noam Emanuel (CTO and Director).
What does PolyPid Ltd. do?
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing locally administered therapies to improve surgical outcomes. As of March 2025, it has a market cap of $35.97 million and reported a net profit loss of $8 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read